strong full-year outlook adjust
rev bln cons/cs bln y/i adjust
ebit mln cons/cs mln y/i adjust ep came
cons/cs y/i adjust gross margin
bp y/i ebit margin came
unchang y/i beat rel cse larg driven top line
gm ebit margin essenti in-lin expect
segment perform pharma distribut servic report rev bln
cons/cs bln y/i rev segment came
bln oper incom pharma distribut servic mln
cons/cs mln y/i oper incom came
mln cons/cs mln y/i compani attribut y/i
increas pharma distribut servic segment primarili organ growth
largest custom increas specialti product sale overal market growth
perform mwi world courier
guidanc updat incorpor impact updat
outlook reflect continu strong perform opportunist share repurchas
incorpor potenti impact specif
lower adjust ep outlook previous
compani expect revenu growth lsd-msd msd-hsd previous
consolid adjust ebit growth expect lsd-msd widen msd
seen lsd-msd widen msd rang previous oper incom
expect declin lsd rang revis growth hsd rang final
see weight averag dilut share mln rang million
previous target price roughli ebitda estim risk
competit pressur slow healthcar util trend script growth increas
gener deflat weaker brand inflat advers opioid litig
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
global pharmaceut sourc distribut
better fundament perform sentiment well better
expect outcom opioid litig could drive upsid target price
blue sky scenario
weaker fundament perform sentiment wors expect
outcom opioid litig could lead downsid versu target price
grey sky scenario
 close
compani mention price
analyst identifi report certifi respect compani secur individu analyz view
express report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
